Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Oppenheimer boosted their FY2021 EPS estimates for shares of Alnylam Pharmaceuticals in a research report issued on Wednesday, January 12th. Oppenheimer analyst L. Gershell now expects that the biopharmaceutical company will earn ($6.30) per share for the year, up from their previous forecast of ($6.37). Oppenheimer has a “Outperform” rating and a $200.00 price objective on the stock. Oppenheimer also issued estimates for Alnylam Pharmaceuticals’ Q4 2021 earnings at ($1.26) EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, October 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.51) by ($0.21). The company had revenue of $187.63 million for the quarter, compared to analyst estimates of $218.69 million. Alnylam Pharmaceuticals had a negative net margin of 111.82% and a negative return on equity of 94.37%. The firm’s revenue was up 49.1% on a year-over-year basis. During the same period in the previous year, the business earned ($2.18) EPS.
ALNY opened at $148.50 on Friday. The company has a quick ratio of 4.22, a current ratio of 4.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $17.76 billion, a P/E ratio of -20.83 and a beta of 0.88. Alnylam Pharmaceuticals has a 52 week low of $125.08 and a 52 week high of $212.00. The business’s fifty day simple moving average is $175.66 and its 200 day simple moving average is $184.19.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 33,978 shares of the firm’s stock in a transaction that occurred on Friday, November 12th. The stock was sold at an average price of $171.52, for a total transaction of $5,827,906.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Akshay Vaishnaw sold 2,879 shares of the firm’s stock in a transaction that occurred on Thursday, December 23rd. The shares were sold at an average price of $190.93, for a total value of $549,687.47. The disclosure for this sale can be found here. Company insiders own 2.30% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Natixis Advisors L.P. acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $1,931,000. Y Intercept Hong Kong Ltd grew its position in shares of Alnylam Pharmaceuticals by 101.9% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 7,592 shares of the biopharmaceutical company’s stock worth $1,287,000 after acquiring an additional 3,832 shares in the last quarter. International Biotechnology Trust PLC grew its position in shares of Alnylam Pharmaceuticals by 36.9% in the 2nd quarter. International Biotechnology Trust PLC now owns 149,000 shares of the biopharmaceutical company’s stock worth $25,239,000 after acquiring an additional 40,200 shares in the last quarter. Worldquant Millennium Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 11.4% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 31,999 shares of the biopharmaceutical company’s stock worth $5,424,000 after acquiring an additional 3,271 shares in the last quarter. Finally, Security National Bank of Sioux City Iowa IA acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $254,000. Hedge funds and other institutional investors own 92.06% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
Featured Article: Overweight
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.